Idiopathic pulmonary fibrosis: The association between the adaptive multiple features method and fibrosis outcomes

American Journal of Respiratory and Critical Care Medicine

Volumn 195, Issue 7, 2017, Pages 921-929

  Salisbury, Margaret L ^a   Lynch, David A ^b   Van Beek, Edwin J R ^c   Kazerooni, Ella A ^a   Guo, Junfeng ^d   Xia, Meng ^e   Murray, Susan ^e   Anstrom, Kevin J ^f,g   Yow, Eric ^g   Martinez, Fernando J ^h   Hoffman, Eric A ^d   Flaherty, Kevin R ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b DEPARTMENT OF MEDICINE   (United States)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

^d UNIVERSITY OF IOWA   (United States)

^e UNIVERSITY OF MICHIGAN   (United States)

^f DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g DUKE UNIVERSITY MEDICAL CENTER   (United States)

^h WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Idiopathic pulmonary fibrosis; Multidetector computed tomography; Prognosis

Indexed keywords

ACETYLCYSTEINE; AZATHIOPRINE; PREDNISONE;

AGED; ARTICLE; CELL DENSITY; DISEASE COURSE; FEMALE; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HOSPITALIZATION; HUMAN; IMAGE ANALYSIS; LUNG EMPHYSEMA; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; DIAGNOSTIC IMAGING; IMAGE PROCESSING; LUNG; LUNG FUNCTION TEST; PATHOPHYSIOLOGY; PROCEDURES; PROSPECTIVE STUDY; STATISTICS AND NUMERICAL DATA; X-RAY COMPUTED TOMOGRAPHY;

AGED; DISEASE PROGRESSION; FEMALE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; IMAGE PROCESSING, COMPUTER-ASSISTED; LUNG; MALE; PROSPECTIVE STUDIES; RESPIRATORY FUNCTION TESTS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 85017340618     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201607-1385OC     Document Type: Article

References (40)

1. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, et al. ; ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement: Idiopathic pulmonary fibrosis: Evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011;183:788-824.
2. Sumikawa H, Johkoh T, Colby TV, Ichikado K, Suga M, Taniguchi H, Kondoh Y, Ogura T, Arakawa H, Fujimoto K, et al. Computed tomography findings in pathological usual interstitial pneumonia: Relationship to survival. Am J Respir Crit Care Med 2008;177:433-439.
3. Walsh SL, Calandriello L, Sverzellati N, Wells AU, Hansell DM; UIP Observer Consort. Interobserver agreement for the ATS/ERS/JRS/ALAT criteria for a UIP pattern on CT. Thorax 2016;71:45-51.
4. Watadani T, Sakai F, Johkoh T, Noma S, Akira M, Fujimoto K, Bankier AA, Lee KS, Mü ller NL, Song JW, et al. Interobserver variability in the CT assessment of honeycombing in the lungs. Radiology 2013;266: 936-944.
5. Kliment CR, Araki T, Doyle TJ, Gao W, Dupuis J, Latourelle JC, Zazueta OE, Fernandez IE, Nishino M, Okajima Y, et al. A comparison of visual and quantitative methods to identify interstitial lung abnormalities. BMC Pulm Med 2015;15:134.
6. Maldonado F, Moua T, Rajagopalan S, Karwoski RA, Raghunath S, Decker PA, Hartman TE, Bartholmai BJ, Robb RA, Ryu JH. Automated quantification of radiological patterns predicts survival in idiopathic pulmonary fibrosis. Eur Respir J 2014;43:204-212.
7. Rosas IO, Yao J, Avila NA, Chow CK, Gahl WA, Gochuico BR. Automated quantification of high-resolution CT scan findings in individuals at risk for pulmonary fibrosis. Chest 2011;140:1590-1597.
8. Best AC, Lynch AM, Bozic CM, Miller D, Grunwald GK, Lynch DA. Quantitative CT indexes in idiopathic pulmonary fibrosis: Relationship with physiologic impairment. Radiology 2003;228: 407-414.
9. Best AC, Meng J, Lynch AM, Bozic CM, Miller D, Grunwald GK, Lynch DA. Idiopathic pulmonary fibrosis: Physiologic tests, quantitative CT indexes, and CT visual scores as predictors of mortality. Radiology 2008;246:935-940.
10. Uppaluri R, Hoffman EA, Sonka M, Hunninghake GW, McLennan G. Interstitial lung disease: A quantitative study using the adaptive multiple feature method. Am J Respir Crit Care Med 1999;159: 519-525.
11. Uppaluri R, Mitsa T, Sonka M, Hoffman EA, McLennan G. Quantification of pulmonary emphysema from lung computed tomography images. Am J Respir Crit Care Med 1997;156:248-254.
12. Xu Y, van Beek EJ, Hwanjo Y, Guo J, McLennan G, Hoffman EA. Computeraided classification of interstitial lung diseases via MDCT: 3D adaptive multiple feature method (3D AMFM). Acad Radiol 2006;13:969-978.
13. Uppaluri R, Hoffman EA, Sonka M, Hartley PG, Hunninghake GW, McLennan G. Computer recognition of regional lung disease patterns. Am J Respir Crit Care Med 1999;160:648-654.
14. Martinez FJ, de Andrade JA, Anstrom KJ, King TE Jr, Raghu G; Idiopathic Pulmonary Fibrosis Clinical Research Network. Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2014;370:2093-2101.
15. Raghu G, Anstrom KJ, King TE Jr, Lasky JA, Martinez FJ; Idiopathic Pulmonary Fibrosis Clinical Research Network. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med 2012;366:1968-1977.
16. Salisbury ML, van Beek EJ, Kazerooni EA, Guo J, Xia M, Murray S, Anstrom KJ, Yow E, Martinez FJ, Hoffman EA, et al. Association of adaptive multiple features method measures of fibrosis with outcomes in idiopathic pulmonary fibrosis [abstract]. International Colloquium on Lung and Airway Fibrosis, Dublin, Ireland, September 24-18, 2016.
17. Macintyre N, Crapo RO, Viegi G, Johnson DC, van der Grinten CP, Brusasco V, Burgos F, Casaburi R, Coates A, Enright P, et al. Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur Respir J 2005;26:720-735.
18. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, et al. ; ATS/ERS Task Force. Standardisation of spirometry. Eur Respir J 2005;26:319-338.
19. Hansell DM, Bankier AA, MacMahon H, McLoud TC, Mü ller NL, Remy J. Fleischner Society: Glossary of terms for thoracic imaging. Radiology 2008;246:697-722.
20. Zisman DA, Schwarz M, Anstrom KJ, Collard HR, Flaherty KR, Hunninghake GW; Idiopathic Pulmonary Fibrosis Clinical Research Network. A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J Med 2010;363:620-628.
21. Marasini D, Quatto P, Ripamonti E. Assessing the inter-rater agreement for ordinal data through weighted indexes. Stat Methods Med Res 2014;25:1-23.
22. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986;1:307-310.
23. Ley B, Elicker BM, Hartman TE, Ryerson CJ, Vittinghoff E, Ryu JH, Lee JS, Jones KD, Richeldi L, King TE Jr, et al. Idiopathic pulmonary fibrosis: CT and risk of death. Radiology 2014;273:570-579.
24. Ley B, Ryerson CJ, Vittinghoff E, Ryu JH, Tomassetti S, Lee JS, Poletti V, Buccioli M, Elicker BM, Jones KD, et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med 2012;156:684-691.
25. Schmidt SL, Tayob N, Han MK, Zappala C, Kervitsky D, Murray S, Wells AU, Brown KK, Martinez FJ, Flaherty KR. Predicting pulmonary fibrosis disease course from past trends in pulmonary function. Chest 2014; 145:579-585.
26. Salisbury ML, Xia M, Zhou Y, Murray S, Tayob N, Brown KK, Wells AU, Schmidt SL, Martinez FJ, Flaherty KR. Idiopathic pulmonary fibrosis: Gender-age-physiology index stage for predicting future lung function decline. Chest 2016;149:491-498.
27. Ley B, Bradford WZ, Vittinghoff E, Weycker D, du Bois RM, Collard HR. Predictors of mortality poorly predict common measures of disease progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2016;194:711-718.
28. Daniels CE, Lasky JA, Limper AH, Mieras K, Gabor E, Schroeder DR; Imatinib-IPF Study Investigators. Imatinib treatment for idiopathic pulmonary fibrosis: Randomized placebo-controlled trial results. Am J Respir Crit Care Med 2010;181:604-610.
29. Demedts M, Behr J, Buhl R, Costabel U, Dekhuijzen R, Jansen HM, MacNee W, Thomeer M, Wallaert B, Laurent F, et al. ; IFIGENIA Study Group. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2005;353:2229-2242.
30. King TE Jr, Behr J, Brown KK, du Bois RM, Lancaster L, de Andrade JA, Stä hler G, Leconte I, Roux S, Raghu G. BUILD-1: A randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2008;177:75-81.
31. King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, Gorina E, Hopkins PM, Kardatzke D, Lancaster L, et al. ; ASCEND Study Group. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014;370: 2083-2092.
32. Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, King TE Jr, Lancaster L, Sahn SA, Szwarcberg J, et al. ; CAPACITY Study Group. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): Two randomised trials. Lancet 2011; 377:1760-1769.
33. Raghu G, Brown KK, Bradford WZ, Starko K, Noble PW, Schwartz DA, King TE Jr; Idiopathic Pulmonary Fibrosis Study Group. A placebocontrolled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med 2004;350:125-133.
34. Raghu G, Brown KK, Costabel U, Cottin V, du Bois RM, Lasky JA, Thomeer M, Utz JP, Khandker RK, McDermott L, et al. Treatment of idiopathic pulmonary fibrosis with etanercept: An exploratory, placebo-controlled trial. Am J Respir Crit Care Med 2008;178: 948-955.
35. Park HJ, Lee SM, Song JW, Lee SM, Oh SY, Kim N, Seo JB. Texturebased automated quantitative assessment of regional patterns on initial CT in patients with idiopathic pulmonary fibrosis: Relationship to decline in forced vital capacity. Am J Roentgenol 2016;207: 976-983.
36. Kim HJ, Brown MS, Chong D, Gjertson DW, Lu P, Kim HJ, Coy H, Goldin JG. Comparison of the quantitative CT imaging biomarkers of idiopathic pulmonary fibrosis at baseline and early change with an interval of 7 months. Acad Radiol 2015;22:70-80.
37. Collard HR, King TE Jr, Bartelson BB, Vourlekis JS, Schwarz MI, Brown KK. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2003;168: 538-542.
38. Flaherty KR, Andrei AC, Murray S, Fraley C, Colby TV, Travis WD, Lama V, Kazerooni EA, Gross BH, Toews GB, et al. Idiopathic pulmonary fibrosis: Prognostic value of changes in physiology and six-minutewalk test. Am J Respir Crit Care Med 2006;174:803-809.
39. Latsi PI, du Bois RM, Nicholson AG, Colby TV, Bisirtzoglou D, Nikolakopoulou A, Veeraraghavan S, Hansell DM, Wells AU. Fibrotic idiopathic interstitial pneumonia: The prognostic value of longitudinal functional trends. Am J Respir Crit Care Med 2003;168:531-537.
40. Hoffman EA, Reinhardt JM, Sonka M, Simon BA, Guo J, Saba O, Chon D, Samrah S, Shikata H, Tschirren J, et al. Characterization of the interstitial lung diseases via density-based and texture-based analysis of computed tomography images of lung structure and function. Acad Radiol 2003;10:1104-1118. ORIGINAL ARTICLE